Lonza has added a dedicated Early Phase Clinical Manufacturing facility at its Small Molecules site in Bend, Oregon, providing additional capacity for solutions to complex bioavailability challenges in clinical projects.   Additionally, capabilities for development and clinical manufacture have been added. This enables Lonza to speed up product delivery, which is crucial in its customers’ rapid journey towards clinical trials.   The facility features eleven suites in total, seven of wh...